Annovis Bio, Inc. financial data

Symbol
ANVS on NYSE
Location
Malvern, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 345% % -58%
Debt-to-equity 22% %
Return On Equity -153% % -105%
Return On Assets -126% % 71%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,502,889 shares 92%
Common Stock, Shares, Outstanding 20,187,904 shares 52%
Entity Public Float $51,312,050 USD -44%
Common Stock, Value, Issued $2,019 USD 52%
Weighted Average Number of Shares Outstanding, Basic 19,685,071 shares 52%
Weighted Average Number of Shares Outstanding, Diluted 19,685,071 shares 52%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $21,470,358 USD -10%
General and Administrative Expense $5,253,623 USD -19%
Operating Income (Loss) $26,723,981 USD 12%
Nonoperating Income (Expense) $1,839,537 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $40,939,110 USD 1.9%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $24,884,444 USD 39%
Earnings Per Share, Basic -1 USD/shares 61%
Earnings Per Share, Diluted -1 USD/shares 74%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $15,286,399 USD 21%
Assets, Current $7,813,295 USD -69%
Assets $17,188,961 USD 20%
Accounts Payable, Current $2,112,026 USD -48%
Employee-related Liabilities, Current $706,650 USD 28%
Liabilities, Current $3,733,797 USD -31%
Liabilities $4,032,797 USD -45%
Retained Earnings (Accumulated Deficit) $153,869,247 USD -19%
Stockholders' Equity Attributable to Parent $13,156,164 USD 86%
Liabilities and Equity $17,188,961 USD 20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,099,164 USD -15%
Net Cash Provided by (Used in) Financing Activities $19,783,423 USD 348%
Common Stock, Shares Authorized 70,000,000 shares 0%
Common Stock, Shares, Issued 20,187,904 shares 52%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,684,259 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15,286,399 USD 21%
Deferred Tax Assets, Valuation Allowance $37,240,555 USD 24%
Deferred Tax Assets, Gross $37,240,555 USD 24%
Deferred Tax Assets, Operating Loss Carryforwards $13,634,896 USD 42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2,000,000 shares 0%
Additional Paid in Capital $167,023,392 USD 23%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $444,647 USD 13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%